Examine the rise of personalized and biomarker-driven therapies, the logistical challenges of rare patient populations, and ...

The FDA has launched a secure, GovCloud-based agentic AI system to support regulatory workflows across review divisions, ...

A new global Tufts CSDD survey of 387 investigative site professionals reveals broad experience with digital and decentralized trial tools, growing site-driven technology investments, and strong ...

A new global Tufts CSDD survey of 387 investigative site professionals reveals broad experience with digital and decentralized trial tools, growing site-driven technology investments, and strong ...

“FDA's talented reviewers have been creative and proactive in deploying AI capabilities—agentic AI will give them a powerful tool to streamline their work and help them ensure the safety and efficacy ...